Robert Atcher - Search Results

Year	Number of Results
2005	2
2007	1
2008	3
2009	2
2010	2
2011	1
2015	1
2016	1
2018	1
2024	0

1

Imaging opportunities in radiation oncology.

Balter JM, Haffty BG, Dunnick NR, Siegel EL; Imaging Opportunities Workshop Participants. Balter JM, et al. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):342-7. doi: 10.1016/j.ijrobp.2010.05.029. Epub 2010 Aug 26. Int J Radiat Oncol Biol Phys. 2011. PMID: 20800378

2

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.

Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, Birnbaum ER, Atcher RW, John KD, Rixe O, Norenberg JP. Makvandi M, et al. Among authors: atcher rw. Target Oncol. 2018 Apr;13(2):189-203. doi: 10.1007/s11523-018-0550-9. Target Oncol. 2018. PMID: 29423595 Review.

3

Synthesis and Preliminary Biological Evaluations of Fluorescent or ¹⁴⁹Promethium Labeled Trastuzumab-Polyethylenimine.

Fitzsimmons J, Nayak T, Cutler C, Atcher R. Fitzsimmons J, et al. Among authors: atcher r. Biomedicines. 2015 Dec 30;4(1):1. doi: 10.3390/biomedicines4010001. Biomedicines. 2015. PMID: 28536369 Free PMC article.

4

Managing the unmanageable.

Atcher RW. Atcher RW. Lancet Oncol. 2009 Aug;10(8):745-6. doi: 10.1016/S1470-2045(09)70208-6. Lancet Oncol. 2009. PMID: 19647197 No abstract available.

5

A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.

Nayak T, Norenberg J, Anderson T, Atcher R. Nayak T, et al. Among authors: atcher r. Cancer Biother Radiopharm. 2005 Feb;20(1):52-7. doi: 10.1089/cbr.2005.20.52. Cancer Biother Radiopharm. 2005. PMID: 15778581

6

Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.

Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A. Su FM, et al. Among authors: atcher r. Nucl Med Biol. 2005 Oct;32(7):741-7. doi: 10.1016/j.nucmedbio.2005.06.009. Nucl Med Biol. 2005. PMID: 16243650

7

Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.

Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP. Nayak TK, et al. Among authors: atcher rw. Nucl Med Biol. 2008 Aug;35(6):673-8. doi: 10.1016/j.nucmedbio.2008.05.003. Nucl Med Biol. 2008. PMID: 18678352 Free PMC article.

8

Improved safety and efficacy of ²¹³Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine.

Chan HS, Konijnenberg MW, Daniels T, Nysus M, Makvandi M, de Blois E, Breeman WA, Atcher RW, de Jong M, Norenberg JP. Chan HS, et al. Among authors: atcher rw. EJNMMI Res. 2016 Dec;6(1):83. doi: 10.1186/s13550-016-0240-5. Epub 2016 Nov 21. EJNMMI Res. 2016. PMID: 27873240 Free PMC article.

9

Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.

Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW. Nayak TK, et al. Among authors: atcher rw. Nucl Med Biol. 2007 Feb;34(2):185-93. doi: 10.1016/j.nucmedbio.2006.11.006. Nucl Med Biol. 2007. PMID: 17307126

10

Session 4: strategies for getting the word out.

Atcher R. Atcher R. J Nucl Med. 2008 Jun;49(6):70N-71N. J Nucl Med. 2008. PMID: 18511834 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year